Methods

Genomic Sequencing
Targeted next-generation sequencing was performed (FoundationOne; Foundation Medicine) on a skin biopsy specimen. All exomes of 405 genes as well as introns of 31 cancer-related genes were analyzed using hybridization-based capture (https://www .foundationmedicine.com/). The study and treatment were conducted and informed consent obtained in accordance with the Declaration of Helsinki, UCSD Moores Cancer Center, and MD Anderson Cancer Center internal review board requirements.
IL-6 Quantitation
Interleukin 6 levels were assayed using a commercial enzyme linked immunoassay kit (ELISA; Quantikine R&D Systems) per manufacturer's instructions.
Report of a Case
The patient is a female currently in her 50s, who was healthy until she developed multiple plaques on the face and neck. 6 There was no disease on scans, nor any systemic symptoms. She was treated with rituximab, valacyclovir, azathioprine, plaquenil, minocycline, and steroids without salutary effects. Skin biopsy results, reviewed by a dermatopathologist, were diagnostic for cutaneous CD. Serum IL-6 levels were within normal range (0.9 pg/mL; lower limit of sensitivity, 0.7 pg/mL). Median levels for 118 patients with diffuse large-cell lymphoma were 4.6 pg/mL (range, undetectable to 225 pg/mL); median levels for 50 healthy volunteers were undetectable (range, undetectable to 4.3 pg/mL). 7 The patient was both human immunodeficiency virus and human herpesvirus 8 negative. The patient was enrolled in a clinical trial with intravenous siltuximab 12 mg/kg administered every 3 weeks. As reported previously, her skin lesions improved within 24 hours 6 ( Figure 2 ) and she experienced no adverse effects. Patient attained a CR, which was durable on treatment for 7 years, despite increasing the time interval between treatment infusions to every 6 weeks. Treatment was then discontinued on her request and, within 1 year, she relapsed in the cutaneous area of the neck. She resumed intravenous siltuximab 12 mg/kg every 3 weeks and experienced rapid improvement of skin lesions. At the time of relapse, diagnosis was confirmed by repeat biopsy. Tissue was also sent for next-generation sequencing.
Results and Discussion
This patient with cutaneous CD attained a durable CR on anti-IL-6 treatment despite having normal serum IL-6 levels, the latter being consistent with previous reports demonstrating that localized CD without systemic manifestations lacks increased IL-6 gene expression in lymphoid tissue. 8 Next-generation sequence studies showing an alteration in JAK1 may explain these findings because this alteration could sensitize the IL-6/IL-6R/ gp130/JAK1 machinery to normal levels of ligand. The patient harbored a JAK1 V310I missense mutation, as well as a subclonal alteration in Notch1
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. The JAK1 locus of V310 is found within the FERM (4.1/ezrin/radixin/moesin) domain. JAK family members share 4 common structural domains ( Figure 3 ). JAKs and FAKs are the only tyrosine kinases with FERM domains, which are divergent from other ERM (ezrin, radixin, moesin) proteins. 9 The FERM domain regulates protein localization, often at the plasma membrane, via intermolecular interactions. The most N-terminal region of the FERM domain of JAKs mediates interaction with type I and II cytokine
Key Points
Question What potential molecular aberration(s) may help explain the exceptional response observed in a patient with cutaneous Castleman disease treated with the anti-interleukin-6 (anti-IL-6) antibody siltuximab?
Findings In this case report, a missense mutation in the Janus Kinase 1 gene (JAK1
V310I
) was identified, which is a crucial signaling component of the IL-6/IL-6 receptor/gp130 machinery. JAK1 V310I may induce a conformational change that drives Castleman disease by enabling activation of the IL-6R/gp130/JAK1 complex even in the presence of normal levels of IL-6.
Meaning Genomic profiling of Castleman disease may reveal important molecular drivers of disease, treatment resistance, and therapeutic targets. deed, many of the gain-of-function mutations found within the JAK mutational hot-spot, located within pseudokinase region, require a functional FERM domain capable of mediating interactions with receptors in order for signaling events to occur.
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JAK1
V310I mutations have been reported previously in solid malignancies (http://cancer.sanger.ac.uk). Support for the functional significance of this amino acid substitution comes from the most common patient-derived gain-of-function mutations occurring in the pseudokinase domain observed in myeloproliferative neoplasms-the JAK1 V658F and the corresponding JAK2 V617F/V617I mutations. 12, 14 The substitution of V658F in JAK1, or other amino acid changes (eg, valine to isoleucine), resulting in increasing hydrophobic side chains, have a functional impact on JAK1 similar to that of the V658F mutation. 12 Biochemical characterization of the JAK2 V617I mutant identified in patients with myeloproliferative neoplasms also supports the hypothesis that this substitution impacts JAK2 conformation resulting in increasing JAK2 signaling. 14 The precise consequences of the JAK1 V310I mutation are not known, due to the lack of structural information on the JAK1 FERM domain. However, single-particle electron microscopy studies with full-length JAK1 revealed significant conformational flexibility, and suggests that JAK1 makes multiple intermolecular interactions with gp130, along with multiple intramolecular interactions. 15 Full-length JAK1 exists in a closed compact conformation where the FERM domain may make contacts with the kinase domain ( Figure 1 ). 13, 15 This type of compact assembly due to intramolecular interactions between the FERM/kinase domains has also been demonstrated for FAK. 9 We considered the detailed structural information of FAK, which reveals that FERM/kinase domain interactions regulate its activity. Current evidence demonstrates that FAK activation occurs in an orderly and sequential manner, whereby the release of inhibitory interactions between FERM and kinase domains are the initial key steps in full activation of FAK. 9 Here we propose that the JAK1 V310I mutation within the F3 lobe of the FERM domain may also lead JAKs contain 4 functional domains: (1) the FERM (4.1/ezrin/radixin/moesin) domain, (2) the Src homology 2 (SH2) domain, (3) the pseudokinase domain (PK), and (4) the kinase domain. Depicted here are domain structure boundaries for JAK1. The arrow shows the mutation identified in this patient.
